The Drug Regulatory Authority of Pakistan (DRAP) has granted approval to YS Biopharma to initiate a Phase III clinical trial of the PIKA rabies vaccine in Pakistan.

The study will evaluate the immunogenicity and safety of the vaccine in preventing rabies infection.

Developed using YS Biopharma’s proprietary PIKA adjuvant technology, the vaccine is said to accelerate immunity while providing a higher immune response.

Three clinical trials of PIKA including Phase I and Phase II were conducted in Singapore and a Phase I study in China. All three trials have shown that the PIKA rabies vaccine is safe, tolerable, and immunogenic.

YS Biopharma chief medical officer Dr Zenaida Mojares said: “We are delighted to receive approval from DRAP to conduct the PIKA Rabies Vaccine Phase III clinical trial in Pakistan.

“This approval marks a significant milestone in the development of our PIKA Rabies Vaccine as we continue to expand our clinical trial programme globally.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Our progress enables us to advance towards our mission of providing innovative and efficacious vaccines in the fight against a vaccine-preventable rabies disease, with an almost 100% case fatality rate.”

In addition to Pakistan, the company has received approval to conduct a multi-centre, multi-country Phase III study in Singapore, and the Philippines this year.

An estimated 4,500 healthy volunteers without exposure to animal bites are anticipated to participate in Phase III clinical trials.

The company is also planning to conduct more advanced clinical trials of the PIKA Rabies Vaccine in China.

It intends to submit the New Drug Application or Biologics License Application to regulatory authorities in China and countries in Asia and other continents.